1. Scrip
  2. >>Business
  3. >>Deals

Pieris And Seattle Strike IO Deal

 
• By Alexandra Shimmings

Pieris secures another deal for its novel Anticalin technology – this time with Seattle in immuno-oncology.

Communications exchange

Pieris Pharmaceuticals Inc. and Seattle Genetics Inc. have teamed up to develop bispecific immuno-oncology therapies for solid and blood cancers using both firms' core technologies, Anticalins and antibody-drug conjugates.

The idea is to develop novel antibody-anticalin fusion proteins using the core technologies of both companies: Pieris' proprietary suite of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

EY Recommends Focusing On Fundamentals, Waiting For Prime Deal Conditions

 
• By Joseph Haas

Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.